Foresite Capital Management V, LLC

10% Owner

Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001792206

Purchase history

Companies traded: 3
Purchases · 12M: 5
Purchases · 24M: 6
Average purchase: $2.4M
Median purchase: $1.8M
Gross purchase value: $14.3M

Companies: ALUMIS INC. | Eikon Therapeutics, Inc. | Latigo Biotherapeutics, Inc.

6 SEC accession(s) · 6 joint-owner event(s). Values are reported Form 4 transaction values in USD.

Qualifying purchase disclosures

Published	Company	Ticker	Role	Reported value	SEC source
2026-08-10	Latigo Biotherapeutics, Inc.	LTGO	10% Owner	$2.5M	Open filing
2026-02-06	Eikon Therapeutics, Inc.	EIKN	10% Owner	$1,000.0K	Open filing
2026-01-12	ALUMIS INC.	ALMS	10% Owner	$7.0M	Open filing
2025-11-25	ALUMIS INC.	ALMS	10% Owner	$532.9K	Open filing
2025-11-19	ALUMIS INC.	ALMS	10% Owner	$3.1M	Open filing
2025-05-06	ALUMIS INC.	ALMS	10% Owner	$202.3K	Open filing

Post-purchase outcomes

Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.

Period	Completed events	Price coverage	Hit rate	Median excess return	Average excess return	Worst excess return
5D	4Small Sample	66.7% (4/6)	75.0% (3/4)	+9.7%	+10.7%	-2.5%
20D	4Small Sample	66.7% (4/6)	75.0% (3/4)	+39.7%	+29.4%	-28.3%
60D	4Small Sample	80.0% (4/5)	75.0% (3/4)	+145.8%	+147.5%	-16.6%
120D	4Small Sample	80.0% (4/5)	75.0% (3/4)	+110.5%	+117.4%	-12.8%

Research patterns

First purchase in 12M: 2/5
Large purchase ≥ $100k: 6/6
Cluster buying · 15D: 6/6
Buying the dip: 3/4

Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.

Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.